Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have been given a consensus rating of “Buy” by the sixteen ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $59.62, reflecting a +1.39% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Adocia (Euro ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

European equities traded in the US as American depositary receipts were moving higher late Friday morning, up 0.48% to 1,412.34 on the S&P Europe Select ADR Index, which is relatively flat for the ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the ...